Crispr Therapeutics AG | Mid-cap | Healthcare
$70.19
3.62%
| Crispr Therapeutics Stock Comparison:
Crispr Therapeutics vs VertexCrispr Therapeutics vs RegeneronCrispr Therapeutics vs MadrigalCrispr Therapeutics vs Bio-TechneCrispr Therapeutics vs Corcept TherapeuticsCrispr Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Gross Profit -57.5M
Operating Income -148.4M
Net Income -136.0M
EPS (Diluted) $-1.58

Balance Sheet Metrics

Total Assets 2.2B
Total Liabilities 336.9M
Shareholders Equity 1.8B
Debt to Equity 0.18

Cash Flow Metrics

Operating Cash Flow -96.3M
Free Cash Flow -54.2M

Revenue & Profitability Trend

Crispr Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i35.0M370.0M436.0K913.1M543.0K
Cost of Goods Sold i110.2M130.2M110.2M101.2M-
Gross Profit i-75.2M239.8M-109.8M811.9M-
Gross Margin % i-215.0%64.8%-25,186.7%88.9%0.0%
Operating Expenses
Research & Development i320.7M387.3M461.6M340.6M266.9M
Selling, General & Administrative i73.0M76.2M102.5M99.7M88.2M
Other Operating Expenses i-2.3M-1.2M-762.0K-1.9M-176.0K
Total Operating Expenses i391.3M462.3M563.3M438.4M355.0M
Operating Income i-466.6M-222.5M-673.2M373.5M-354.4M
Operating Margin % i-1,333.0%-60.1%-154,394.7%40.9%-65,273.5%
Non-Operating Items
Interest Income i-----
Interest Expense i-----
Other Non-Operating Income103.9M71.8M22.7M6.0M6.4M
Pre-tax Income i-362.7M-150.7M-650.5M379.5M-348.1M
Income Tax i3.6M2.9M-325.0K1.9M809.0K
Effective Tax Rate % i0.0%0.0%0.0%0.5%0.0%
Net Income i-366.3M-153.6M-650.2M377.7M-348.9M
Net Margin % i-1,046.4%-41.5%-149,122.7%41.4%-64,247.7%
Key Metrics
EBITDA i-447.3M-202.7M-649.0M391.5M-345.3M
EPS (Basic) i$-4.34$-1.94$-8.36$4.97$-5.29
EPS (Diluted) i$-4.34$-1.94$-8.36$4.70$-5.29
Basic Shares Outstanding i8435912679220930777465757594868665949672
Diluted Shares Outstanding i8435912679220930777465757594868665949672

Income Statement Trend

Crispr Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i298.3M389.5M211.9M923.0M1.2B
Short-term Investments i1.6B1.3B1.6B1.5B521.7M
Accounts Receivable i25.0M200.0M0305.0K144.0K
Inventory i-----
Other Current Assets8.3M14.4M37.7M38.1M-
Total Current Assets i1.9B1.9B1.9B2.4B1.7B
Non-Current Assets
Property, Plant & Equipment i185.5M195.4M194.8M204.6M76.2M
Goodwill i016.0K71.0K125.0K180.0K
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets27.3M13.6M16.3M22.2M18.1M
Total Non-Current Assets i304.9M321.5M390.0M334.4M111.3M
Total Assets i2.2B2.2B2.2B2.8B1.8B
Liabilities
Current Liabilities
Accounts Payable i14.7M38.1M27.4M14.8M9.1M
Short-term Debt i17.3M15.6M15.8M12.2M11.4M
Current Portion of Long-term Debt-----
Other Current Liabilities10.4M5.1M20.0K171.0K7.2M
Total Current Liabilities i87.8M108.8M121.1M119.9M94.3M
Non-Current Liabilities
Long-term Debt i206.4M223.0M228.2M212.9M50.1M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities3.4M958.0K6.0M7.3M7.6M
Total Non-Current Liabilities i222.2M238.0M246.5M232.5M69.5M
Total Liabilities i310.0M346.8M367.6M352.4M163.7M
Equity
Common Stock i2.7M2.5M2.4M2.4M2.3M
Retained Earnings i-1.4B-999.7M-846.1M-195.9M-573.6M
Treasury Stock i62.0K62.0K63.0K63.0K63.0K
Other Equity-----
Total Shareholders Equity i1.9B1.9B1.9B2.4B1.7B
Key Metrics
Total Debt i223.7M238.6M244.0M225.0M61.4M
Working Capital i1.8B1.8B1.7B2.3B1.6B

Balance Sheet Composition

Crispr Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-366.3M-153.6M-650.2M377.7M-348.9M
Depreciation & Amortization i19.3M19.8M24.2M18.0M9.2M
Stock-Based Compensation i86.6M81.0M97.9M102.4M66.0M
Working Capital Changes i178.3M-196.6M13.1M3.3M-9.6M
Operating Cash Flow i-120.8M-263.3M-502.5M515.4M-281.5M
Investing Activities
Capital Expenditures i-1.9M-9.5M-37.2M-81.7M-18.4M
Acquisitions i-----
Investment Purchases i-1.5B-1.1B-1.4B-1.5B-594.0M
Investment Sales i1.2B1.5B1.2B555.6M71.2M
Investing Cash Flow i-280.5M377.1M-258.7M-1.0B-541.2M
Financing Activities
Share Repurchases i----0
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i300.7M32.7M970.0K213.3M982.3M
Free Cash Flow i-144.7M-272.3M-532.9M457.3M-256.7M
Net Change in Cash i-100.6M146.5M-760.2M-306.8M159.7M

Cash Flow Trend

Crispr Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -15.61
Forward P/E -13.44
Price to Book 3.50
Price to Sales 161.92
PEG Ratio -0.26

Profitability Ratios

Profit Margin -215.00%
Operating Margin -14,918.27%
Return on Equity -25.34%
Return on Assets -13.05%

Financial Health

Current Ratio 16.61
Debt to Equity 12.59
Beta 1.84

Per Share Data

EPS (TTM) $-5.40
Book Value per Share $19.36
Revenue per Share $0.44

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
crsp6.2B-15.613.50-25.34%-215.00%12.59
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B15.132.0915.34%31.37%9.04
Madrigal 9.9B-20.2314.14-36.30%-54.68%17.81
Bio-Techne 9.8B136.855.083.68%6.02%23.14
Corcept Therapeutics 9.3B78.7114.6021.70%18.67%1.04

Financial data is updated regularly. All figures are in the company's reporting currency.